• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 10-12 December 2025 in London

by chantal | Dec 10, 2025 | iSCIB1+, SCIB1, Vaccine, Vaccines

Kate Young, Samantha Paston, Heather Shaw, Pippa Corrie, Sarah Danson, Miranda Payne, Poulam Patel, Ioannis Karydis, Satish Kumar, Clare Barlow, Rebecca Lee, Martin Highley, Kellati Prasad, Georgia Goodhew, Gaëlle Cane, Joseph Chadwick, Sabaria Shah, Nermeen Varawalla...

Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers

by chantal | Dec 1, 2024 | Media Coverage, Modi-2, Moditope, Moditope, Vaccines

Abdullah Al-Omari , Katherine Cook, Peter Symonds, Anne Skinner, Alissa Wright, Yaling Zhu, Vincent Coble, Omar Mohammed, Ruhul Choudhury, Nazim Uddin, Priscilla Ranglani, Adrian Parry, Sally Adams, Geoffrey Lynn, Lindy Durrant, & Victoria Brentville...

Annual Meeting of the American Society of Clinical Oncology (ASCO), 31 May – 4 June 2024, Chicago, Illinois, USA

by admin | Aug 2, 2024 | Immunobody, Vaccines

Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Kellati Prasad, Clare Barlow, Kate Young, Ioannis Karydis, Philippa Corrie, Maria Marples, Rebecca Lee, Robert Miller, and Lindy Durrant

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024

by chantal | Jun 11, 2024 | Modi-1, SCIB1, Vaccines

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma Samantha Paston, Heather Shaw, Poulam Patel, Miranda...

Annual Meeting of The American Association for Cancer Research (AACR), April 2024 in San Diego, California, USA

by admin | Apr 30, 2024 | Immunobody, Vaccines

Efficacy and safety results from the open-label Phase 2 SCOPE trial

by admin | Nov 17, 2023 | Immunobody, Vaccines

Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Dennis Hadjiyiannakis, Clare Barlow, Martin Highley, Amna Sheri, Amanda Fitzpatrick, Ioannis Karydis, Maria Marples, Robert Miller, Fayaz Master and Lindy Durrant
« Older Entries

Recent Posts

  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy